Agilent attributes its success in part to a “Build and Buy” approach that combines internal growth with external acquisitions—$2.9 billion in mergers and acquisitions since FY 2015—as well as capital investment, dividends and share repurchases. For FY 2022, Agilent has issued guidance to investors projecting between $6.65 billion and $6.73 billion, with year-over-year core revenue growth of between five and a half and seven percent . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Agilent CEO: “We’re Not Just a One-Year Wonder!” appeared first on GEN – Genetic Engineering and Biotechnology News.
